ARMY: Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

Sponsor

Menarini Group (Industry)

Overall Status

Terminated

CT.gov ID

NCT02353143

Collaborator

(none)

Enrollment

Locations

Arm

76.3

Actual Duration (Months)

2.4

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion, in patients with relapsed or refractory AML. Pharmacokinetics, clinical activity and potential immunogenicity of MEN1112 will be evaluated as well.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Adult Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse	Drug: MEN1112	Phase 1

Detailed Description

This trial is designed as an open label, non randomised, dose escalation and cohort expansion, first administration to human study to be conducted in approximately 20 European sites. The study is aiming to identify the Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), to assess the pharmacokinetics and to determine the clinical activity and potential immunogenicity of MEN1112, administered as IV infusion for two 21-day cycles.

Approximately 100 male and female ≥ 18 years-old patients, with a documented diagnosis of relapsed or refractory AML (not M3 FAB subtype), will be treated in the study, which consists of two steps.

Step 1 is the dose escalation phase according to a 3+3 patients cohort design. Incremental mg/Kg doses will be tested. Briefly, MEN1112 doses are to be administered to 3 patients; if no DLT is observed in a cohort of 3 DLT evaluable patients at a given dose level, the next cohort of 3 new patients will be treated with the next higher dose. In case of DLT occurrence by one of the three patients at any dose, the cohort will be expanded to 6 DLT evaluable patients at the same dose level. If two or more patients at a given dose level exhibit DLT, the dose escalation phase will be concluded as the MTD will be identified as one dose level below the one at which ≥ 2 DLT out of 6 treated patients occur.

Step 2 is the cohort expansion phase which will include patients treated at the MTD or the maximum dose level judged to be tolerable.

In each study Step, patients will be given two induction cycles of MEN1112 followed by a four-week End of Treatment period and a Follow-up period. In Step 1 and Step 2, DLT and MTD will be assessed when MEN1112 is given as a 'one shot' infusion (first group of patients) for all doses as well as a 'ramp up' administration to be infused in 3 days for the first two doses in Cycle 1 (second group of patients).

Along the study period, adverse events, changes in hematology/serum biochemistry parameters and bone marrow treatment response will represent the major clinical findings to be monitored on regular basis. The individual experimental clinical phase will last up to 6 months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration) encompassing approx. 40 planned visits at site, including Screening,Treatment, End of Treatment, Follow-up period and the End of Study visit.

Study Design

Study Type:

Interventional

Actual Enrollment :

71 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.

Actual Study Start Date :

Dec 1, 2014

Actual Primary Completion Date :

Apr 9, 2021

Actual Study Completion Date :

Apr 9, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MEN1112 Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation	Drug: MEN1112 Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients). Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).

Arm

Intervention/Treatment

Experimental: MEN1112

Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation

Drug: MEN1112

Intravenous infusion of MEN1112 pro/Kg body weight dose will be administered for two 21-day cycles; MEN1112 dose is administered as' one shot infusion' (first group of patients) and as a dose to be infused in 3 days for the first two doses in Cycle 1 (second group of patients). Two treatment cycles will be followed by a 4-week End of Treatment Period and a Follow-up period. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).

Outcome Measures

Primary Outcome Measures

Dose limiting toxicity (DLT) [over 3 weeks after the first dose]
Identification of DLT defined as an adverse event occurring during the first treatment cycle, judged to be related to MEN1112 and meeting any of the following criteria: Grade 3 non-haematological toxicity lasting more than 7 days Grade ≥ 4 non-haematological toxicity.
Maximum tolerated dose (MTD) [over 3 weeks after the first dose]
Identification of MTD defined as one dose level below the Maximum Administered Dose (i.e. one dose level below the one at which ≥ 2 DLTs out of 6 treated patients occur).

Secondary Outcome Measures

Treatment Emergent Signs and Symptoms (TESSs) [6 months]
Incidence, severity, seriousness and treatment related causality of Treatment Emergent Signs and Symptoms (TESSs)
MEN1112 Pharmacokinetic (PK) parameter Cmax [Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.]
Cmax is the maximum serum drug concentration.
MEN1112 PK parameter AUC (0-t) [Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.]
AUC (0-t) is the area under the serum concentration-time curve from time 0 extrapolated to t time
MEN1112 PK parameter AUC (0-∞) [Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.]
AUC (0-∞) is the area under the serum concentration-time curve from time 0 extrapolated to infinite time
MEN1112 PK parameter t1/2 [Under ramp-up schedule during Cycle 1, at the end of Day 1 and 2 infusions (when applicable) and at the end of Day 3 infusion; and under one-shot schedule during Cycle 2, at the end of the third infusion (Day 36). Each cycle lasts 21 days.]
t1/2 is the drug elimination half-life
Complete remission (CR) rate [6 months]
CR rate at any time point, where CR is defined as: bone marrow blasts <5%, absence of extramedullary disease, absolute neutrophil count >1 x 109/L and platelet count > 100 x 109/L
Best response rate [6 months]
best observed response at any time point between CR, CRi [where CRi is defined as: all criteria for CR except residual thrombocytopenia (platelets <100 x 109/L) and/or neutropenia (absolute neutrophil count <1 x 109/L)] and partial remission [(PR): all haematological criteria for CR with bone marrow blasts 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%].
Overall survival [6 months]
number of days between the first study drug administration and death from any cause

Other Outcome Measures

Immunogenicity of MEN1112 [64 days]
Incidence of anti-MEN1112 auto-antibodies

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female patients aged ≥ 18 years.
Documented definitive diagnosis of AML (according to WHO criteria, 2008) that is relapsed/refractory to standard treatment, for which no standard therapy is available or the patient refuses standard therapy.
WBC count ≤ 10 x 109/L at Visit 1/Day 1; hydroxyurea is allowed to lower WBC count.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Visit1/Day

Life expectancy of at least 2 months.
Adequate renal and hepatic laboratory assessments: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to leukemic organ involvement, Total Bilirubin ≤2.0 × ULN, Serum creatinine ≤2.0 × ULN.
Able to give written informed consent before any study related procedure

Exclusion Criteria:

Acute promyelocytic leukaemia (French-American-British M3 classification).
Active central nervous system involvement.
Haematopoietic stem cell transplantation (HSCT) performed within 3 months prior to Screening Visit.
Active infection requiring intravenous antibiotics.
Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety or interfere with the patient's ability to comply with the study activities.
Anti-tumour therapy within 14 days of study Visit 1/Day 1, excluding hydroxyurea.
Prior participation in an investigational study (procedure or device) within 21 days of study Visit 1/Day 1.
Radiotherapy within 28 days prior to study Visit 1/Day 1 or scheduled along the study conduct.
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Other active malignancies. History of malignancy in the last 12 months (except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast or non-melanoma skin cancer).

Contacts and Locations

Locations

	City	Country	Postal Code
1	Antwerp	Belgium	2060
2	Bruxelles	Belgium	1200
3	Liège	Belgium	4000
4	Roeselare	Belgium
5	Yvoir	Belgium	5530
6	Grenoble	France
7	Lille	France	59037
8	Lyon	France	69495
9	Marseille	France	13273
10	Nantes	France	44093
11	Paris	France
12	Pierre-Bénite	France
13	Toulouse	France	31059
14	Villejuif	France	94805
15	Dresden	Germany
16	Essen	Germany	45147
17	Frankfurt	Germany	60590
18	Munich	Germany	81377
19	Bologna	Italy	40126
20	Brescia	Italy	25123
21	Milano	Italy	20132
22	Rome	Italy	00133
23	Torino	Italy	10126
24	Badalona	Spain	08916
25	Barcelona	Spain	08035
26	Pamplona	Spain
27	Salamanca	Spain
28	Sevilla	Spain
29	Valencia	Spain	46026